Can the Sareum share price keep surging?

The Sareum share price has exploded by almost 700% this year, but can it climb even higher? Zaven Boyrazian investigates what’s going on.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

The Sareum (LSE:SAR) share price has been on fire this year. Over the last 12 months, the young biotech company has achieved explosive growth, sending its stock up by nearly 700%. Following its presentation at the BioTrinity 2021 Conference, investor interest has surged. But can the upward momentum continue over the long term? Or is it being driven by speculation? Let’s take a closer look.

The explosive Sareum share price

I’ve explored this business before. But as a quick reminder, Sareum is a young drug developer specialising in discovering treatments for cancer and autoimmune diseases. Like many young biotech firms, the company doesn’t have sufficient funding to develop its products single-handedly. Instead, it sells royalty licenses for its drug candidates to larger, more established pharmaceutical corporations. This provides much-needed capital, and a recurring revenue stream should a drug make it to market.

Recently, Sareum posted some encouraging progress for several of its treatments. SDC-1801, a treatment for severe Covid-19 symptoms, completed its in-vitro studies and provided strong evidence of being significantly more effective than existing anti-inflammatory steroids. As a result, phase one trials are scheduled to commence in early 2022.

Meanwhile, other treatments in its portfolio for autoimmune disease are moving into phase one trials next year as well. And additional patents for its cancer immunotherapy drugs are in the process of being secured. All of this is to say that the firm is achieving several significant product milestones. So, I’m not surprised to see the Sareum share price on the rise.

Taking a step back

The transition out of pre-clinical trials is an achievement many young biotech companies never reach. And with the management team securing additional financing, the firm looks like it’s on track for a prosperous 2022. But as exciting as this is, investors may be getting ahead of themselves.

As it stands, this is a pre-revenue business, excluding the one-time £47,000 generated in 2020. But the rapidly rising Sareum share price has pushed the market capitalisation beyond £230m. While its product pipeline does consist of promising assets, there is no guarantee that they will make it to market. After all, 90% of phase one drugs fail, even with solid pre-clinical results.

With that in mind, it seems to me that this stock’s valuation is being driven by speculation rather than fundamentals. So, I wouldn’t be surprised to see the Sareum share price come crashing down at the first sign of trouble.

The Sareum share price has its risks

Final thoughts

I can’t deny that Sareum and its share price have made impressive progress over the last couple of months. But ultimately my opinion of the company remains unchanged. Without any revenue to support operations, it remains dependent on external financing that may not be available in the future. So, for now, it’s staying on my watchlist.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

How much passive income could a £20,000 ISA provide in a year?

A diversified portfolio of high-yield FTSE shares can build a large and reliable passive income over time, as Royston Wild…

Read more »

Three generation family are playing football together in a field. There are two boys, their father and their grandfather.
Investing Articles

See how much an investor needs in an ISA to fund an £888 monthly passive income

Harvey Jones grabs his calculator to work out how much money people need to generate a decent passive income in…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Value Shares

The BP share price is climbing – see how much £10k invested 1 month ago is worth now

It's been a tough few years for the BP share price. Harvey Jones examines whether the FTSE 100 oil giant…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

Nvidia stock has soared 1,471% in 5 years. Here’s how I’m hunting for the next Nvidia!

Nvidia stock has put in a stunning performance over the past five years. This writer tries to apply some lessons…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

If someone decided to start buying shares with £10k a year ago, here’s what they could be sitting on now!

If someone had started buying shares a year ago with £10k, what might have happened? Our writer outlines some factors…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

The Rolls-Royce share price is close to an all-time record. Could it still be a bargain?

The Rolls-Royce share price has been punching out the lights of late. Our writer thinks things could get even better…

Read more »

4 Teslas in a parking lot at a charger station
Investing Articles

The Tesla share price slips further — how much would £10k invested at the start of the year be worth now?

The Tesla share price remains under pressure, with risks mounting from multiple directions. Here’s what a £10,000 investment would be…

Read more »

British pound data
Investing Articles

The Ocado share price is a sea of red! Time to cut my losses?

Every time Harvey Jones checks out the Ocado share price, he sees red. Will it ever stop falling and leaving…

Read more »